These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25933955)

  • 1. Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression.
    Sałat K; Podkowa A; Kowalczyk P; Kulig K; Dziubina A; Filipek B; Librowski T
    Pharmacol Rep; 2015 Jun; 67(3):465-72. PubMed ID: 25933955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel, highly potent and in vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties.
    Sałat K; Podkowa A; Malikowska N; Kern F; Pabel J; Wojcieszak E; Kulig K; Wanner KT; Strach B; Wyska E
    Neuropharmacology; 2017 Feb; 113(Pt A):331-342. PubMed ID: 27771379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice.
    Thoeringer CK; Erhardt A; Sillaber I; Mueller MB; Ohl F; Holsboer F; Keck ME
    J Psychopharmacol; 2010 May; 24(5):733-43. PubMed ID: 19346277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of anxiolytic-like, anticonvulsant, antidepressant-like and antinociceptive properties of new 2-substituted 4-hydroxybutanamides with affinity for GABA transporters in mice.
    Sałat K; Kulig K; Gajda J; Więckowski K; Filipek B; Malawska B
    Pharmacol Biochem Behav; 2013 Sep; 110():145-53. PubMed ID: 23850524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Anticonvulsant, Antidepressant-, and Anxiolytic-like Effects of an Aqueous Extract from Cultured Mycelia of the Lingzhi or Reishi Medicinal Mushroom Ganoderma lucidum (Higher Basidiomycetes) in Mice.
    Socala K; Nieoczym D; Grzywnowicz K; Stefaniuk D; Wlaz P
    Int J Med Mushrooms; 2015; 17(3):209-18. PubMed ID: 25954905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective GABA transporter inhibitors tiagabine and EF1502 exhibit mechanistic differences in their ability to modulate the ataxia and anticonvulsant action of the extrasynaptic GABA(A) receptor agonist gaboxadol.
    Madsen KK; Ebert B; Clausen RP; Krogsgaard-Larsen P; Schousboe A; White HS
    J Pharmacol Exp Ther; 2011 Jul; 338(1):214-9. PubMed ID: 21450931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of tolerance to the anticonvulsant effects of tiagabine following chronic (21 day) treatment.
    Suzdak PD
    Epilepsy Res; 1994 Dec; 19(3):205-13. PubMed ID: 7698096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of the betaine-GABA transporter (BGT1; slc6a12) gene does not affect seizure thresholds of adult mice.
    Lehre AC; Rowley NM; Zhou Y; Holmseth S; Guo C; Holen T; Hua R; Laake P; Olofsson AM; Poblete-Naredo I; Rusakov DA; Madsen KK; Clausen RP; Schousboe A; White HS; Danbolt NC
    Epilepsy Res; 2011 Jun; 95(1-2):70-81. PubMed ID: 21459558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study.
    Sills GJ; Butler E; Thompson GG; Brodie MJ
    Seizure; 1999 Oct; 8(7):404-11. PubMed ID: 10600581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor.
    Suzdak PD; Jansen JA
    Epilepsia; 1995 Jun; 36(6):612-26. PubMed ID: 7555976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors.
    Dalby NO
    Neuropharmacology; 2000 Sep; 39(12):2399-407. PubMed ID: 10974324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First demonstration of a functional role for central nervous system betaine/{gamma}-aminobutyric acid transporter (mGAT2) based on synergistic anticonvulsant action among inhibitors of mGAT1 and mGAT2.
    White HS; Watson WP; Hansen SL; Slough S; Perregaard J; Sarup A; Bolvig T; Petersen G; Larsson OM; Clausen RP; Frølund B; Falch E; Krogsgaard-Larsen P; Schousboe A
    J Pharmacol Exp Ther; 2005 Feb; 312(2):866-74. PubMed ID: 15550575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Search for new potential anticonvulsants with anxiolytic and antidepressant properties among derivatives of 4,4-diphenylpyrrolidin-2-one.
    Malawska K; Rak A; Gryzło B; Sałat K; Michałowska M; Żmudzka E; Lodarski K; Malawska B; Kulig K
    Pharmacol Rep; 2017 Feb; 69(1):105-111. PubMed ID: 27915183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin.
    Dalby NO; Nielsen EB
    Epilepsy Res; 1997 Jul; 28(1):63-72. PubMed ID: 9255600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic mechanisms of gabitril (tiagabine) and future potential developments.
    Meldrum BS; Chapman AG
    Epilepsia; 1999; 40 Suppl 9():S2-6. PubMed ID: 10612355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze.
    Schmitt U; Hiemke C
    Behav Pharmacol; 1999 Mar; 10(2):131-7. PubMed ID: 10780826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor.
    Nielsen EB; Suzdak PD; Andersen KE; Knutsen LJ; Sonnewald U; Braestrup C
    Eur J Pharmacol; 1991 Apr; 196(3):257-66. PubMed ID: 1832636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral effects of GABA(A) receptor stimulation and GABA-transporter inhibition.
    Schmitt U; Lüddens H; Hiemke C
    Pharmacol Biochem Behav; 2000 Feb; 65(2):351-6. PubMed ID: 10672990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome.
    Oakley JC; Cho AR; Cheah CS; Scheuer T; Catterall WA
    J Pharmacol Exp Ther; 2013 May; 345(2):215-24. PubMed ID: 23424217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy.
    Luszczki JJ; Czuczwar SJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):529-38. PubMed ID: 17204358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.